Esperion Therapeutics Share Price (NASDAQ: ESPR)

$2.06

▲

-0.01

(-0.48%)

Last updated on August 16, 2025 at 1:29 AM IST

$₹

Check the interactive Esperion Therapeutics Stock chart to analyse performance

Esperion Therapeutics stock performance

as on August 16, 2025 at 1:29 AM IST

Today's Low:$2.04
Today's High:$2.18
$2.06
0.97%
Downside
Day's Volatility :6.42%
Upside
5.5%
52 Weeks Low:$0.69
52 Weeks High:$3.94
$2.06
66.38%
Downside
52 Weeks Volatility :82.42%
Upside
47.72%

Esperion Therapeutics Stock Returns

Period	Esperion Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	137.87%	2.3%	0.0%
6 Months	9.89%	-5.9%	0.0%
1 Year	4.85%	-10.9%	0.0%
3 Years	-70.64%	1.7%	-12.4%

Esperion Therapeutics, Inc. Key Stats

Check Esperion Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.07
Open	$2.06
Today's High	$2.18
Today's Low	$2.04
Market Capitalization	$414.4M
Today's Volume	$5.5M
52 Week High	$3.94
52 Week Low	$0.6925
Revenue TTM	$268.1M
EBITDA	$-35.3M
Earnings Per Share (EPS)	$-0.5
Profit Margin	-38.8%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-260.79%

Stock Returns calculator for Esperion Therapeutics Stock including INR - Dollar returns

The Esperion Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Esperion Therapeutics investment value today

Current value as on today

₹1,09,312

Returns

₹9,312

(+9.31%)

Returns from Esperion Therapeutics Stock

₹5,102 (+5.1%)

Dollar Returns*

₹4,210 (+4.21%)

Indian investors sentiment towards Esperion Therapeutics Stock

200%

Period: Jul 16, 2025 to Aug 15, 2025. Change in 30 Days versus previous period

Search interest for Esperion Therapeutics Stock from India on INDmoney has increased by 200% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Esperion Therapeutics, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
7.24%
Vanguard Group Inc
5.74%
Wasatch Advisors LP
5.46%
Bellevue Group AG
4.84%
Two Seas Capital LP
3.46%
Morgan Stanley - Brokerage Accounts
3.29%

Analyst Recommendation on Esperion Therapeutics Stock

Rating

Trend

Buy

71%Buy

28%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Esperion Therapeutics(by analysts ranked 0 to 5 stars)

Esperion Therapeutics Share Price Target

What analysts predicted

Upside of 181.55%

Target:

$5.80

Current:

$2.06

Esperion Therapeutics share price target is $5.80, a slight Upside of 181.55% compared to current price of $2.06 as per analysts' prediction.

Esperion Therapeutics Stock Insights

Price Movement
In the last 1 month, ESPR stock has moved up by 83.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 64.99M → 82.38M (in $), with an average increase of 21.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -40.45M → -4.79M (in $), with an average increase of 744.4% per quarter
ESPR vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 51.9% return, outperforming this stock by 121.9%

Esperion Therapeutics, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$148.4M	↓ 19.57%
Net Income	$-109.0M	↓ 45.98%
Net Profit Margin	-73.48%	↑ 35.92%

	FY20	Y/Y Change
Revenue	$227.5M	↑ 53.37%
Net Income	$-166.2M	↑ 52.44%
Net Profit Margin	-73.04%	↑ 0.44%

	FY21	Y/Y Change
Revenue	$78.4M	↓ 65.52%
Net Income	$-318.8M	↑ 91.84%
Net Profit Margin	-406.42%	↓ 333.38%

	FY22	Y/Y Change
Revenue	$75.5M	↓ 3.79%
Net Income	$-287.8M	↓ 9.73%
Net Profit Margin	-381.34%	↑ 25.08%

	FY23	Y/Y Change
Revenue	$116.3M	↑ 54.14%
Net Income	$-209.2M	↓ 27.3%
Net Profit Margin	-179.87%	↑ 201.47%

	FY24	Y/Y Change
Revenue	$332.3M	↑ 185.66%
Net Income	$-51.7M	↓ 75.27%
Net Profit Margin	-15.57%	↑ 164.3%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$137.7M	↑ 327.09%
Net Income	$61.0M	↓ 208.3%
Net Profit Margin	44.3%	↑ 219.01%

	Q2 FY24	Q/Q Change
Revenue	$73.8M	↓ 46.39%
Net Income	$-61.9M	↓ 201.48%
Net Profit Margin	-83.87%	↓ 128.17%

	Q3 FY24	Q/Q Change
Revenue	$51.6M	↓ 30.07%
Net Income	$-29.5M	↓ 52.32%
Net Profit Margin	-57.18%	↑ 26.69%

	Q4 FY24	Q/Q Change
Revenue	$69.1M	↑ 33.86%
Net Income	$-21.3M	↓ 27.79%
Net Profit Margin	-30.85%	↑ 26.33%

	Q1 FY25	Q/Q Change
Revenue	$65.0M	↓ 5.96%
Net Income	$-40.5M	↑ 89.77%
Net Profit Margin	-62.24%	↓ 31.39%

	Q2 FY25	Q/Q Change
Revenue	$82.4M	↑ 26.76%
Net Income	$-4.8M	↓ 88.16%
Net Profit Margin	-5.82%	↑ 56.42%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-27.2M	↓ 114.77%

	FY20	Y/Y Change
Profit	$225.2M	↓ 926.35%

	FY21	Y/Y Change
Profit	$64.2M	↓ 71.47%

	FY22	Y/Y Change
Profit	$48.5M	↓ 24.48%

	FY23	Y/Y Change
Profit	$73.1M	↑ 50.63%

	FY24	Y/Y Change
Profit	$263.7M	↑ 260.92%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$127.7M	↑ 513.81%

	Q2 FY24	Q/Q Change
Profit	$58.2M	↓ 54.39%

	Q3 FY24	Q/Q Change
Profit	$34.3M	↓ 41.01%

	Q4 FY24	Q/Q Change
Profit	$43.5M	↑ 26.6%

	Q1 FY25	Q/Q Change
Profit	$33.5M	↓ 23.06%

	Q2 FY25	Q/Q Change
Profit	$61.8M	↑ 84.64%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-70.3M	↓ 52.68%
Investing Cash Flow	$64.2M	↓ 54.27%
Financing Cash Flow	$136.2M	↑ 1173.56%

	FY20	Y/Y Change
Operating Cash Flow	$-85.2M	↑ 21.09%
Investing Cash Flow	$21.4M	↓ 66.75%
Financing Cash Flow	$201.7M	↑ 48.11%

	FY21	Y/Y Change
Operating Cash Flow	$-263.8M	↑ 209.72%
Investing Cash Flow	$-50.5M	↓ 336.39%
Financing Cash Flow	$268.2M	↑ 32.96%

	FY22	Y/Y Change
Operating Cash Flow	$-174.8M	↓ 33.73%
Investing Cash Flow	$8.1M	↓ 116.05%
Financing Cash Flow	$32.6M	↓ 87.84%

	FY23	Y/Y Change
Operating Cash Flow	$-135.5M	↓ 22.5%
Investing Cash Flow	$42.5M	↑ 424.43%
Financing Cash Flow	$50.5M	↑ 54.76%

	FY24	Y/Y Change
Operating Cash Flow	$-23.7M	↓ 82.54%
Investing Cash Flow	$-317.0K	↓ 100.75%
Financing Cash Flow	$86.5M	↑ 71.39%

Q1 FY24

Q2 FY24

Q3 FY24

	Q1 FY24	Q/Q Change
Operating Cash Flow	$53.8M	↓ 245.26%
Investing Cash Flow	$-73.0K	-
Financing Cash Flow	$90.6M	↑ 1926.53%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-7.2M	↓ 113.39%
Investing Cash Flow	$-77.0K	↑ 5.48%
Financing Cash Flow	$-30.0M	↓ 133.14%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-35.3M	↑ 390.28%
Investing Cash Flow	$-167.0K	↑ 116.88%
Financing Cash Flow	$-9.1M	↓ 69.71%

Esperion Therapeutics Technicals Summary

Sell

Neutral

Buy

Esperion Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Esperion Therapeutics, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Esperion Therapeutics, Inc.	65.73%	9.89%	4.85%	-70.64%	-93.84%
Haleon Plc Spon Ads	0.57%	-3.45%	-0.36%	57.6%	30.16%
United Therapeutics Corporation	5.34%	-15.99%	-2.43%	41.32%	76.13%
Zoetis Inc.	2.72%	-1.51%	-16.11%	-10.64%	-2.1%
Neurocrine Biosciences Inc.	-0.95%	16.56%	-8.39%	26.59%	13.86%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Esperion Therapeutics, Inc.	NA	NA	-4.78	-0.02	-2.61	-0.06	NA	-2.17
Haleon Plc Spon Ads	21.56	21.56	3.11	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.22	12.22	1.43	26.95	0.19	0.13	NA	158.65
Zoetis Inc.	26.24	26.24	2.42	6.32	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	38.85	38.85	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Esperion Therapeutics, Inc.	Buy	$414.4M	-93.84%	NA	-38.8%
Haleon Plc Spon Ads	Buy	$43.5B	30.16%	21.56	13.81%
United Therapeutics Corporation	Buy	$14.2B	76.13%	12.22	40.36%
Zoetis Inc.	Buy	$67.6B	-2.1%	26.24	27.83%
Neurocrine Biosciences Inc.	Buy	$13.0B	13.86%	38.85	13.88%

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Organization	Esperion Therapeutics
Employees	304
CEO	Mr. Sheldon L. Koenig
Industry	Health Technology

Key Management of Esperion Therapeutics, Inc.

Name	Title
Mr. Sheldon L. Koenig	President, CEO & Director
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer
Mr. Benjamin O. Looker J.D.	General Counsel & Corporate Secretary
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications
Ms. Betty Jean Swartz	Chief Business Officer
Mr. Glenn P. Brame	Chief Technical Operations Officer
Dr. Stephen Pinkosky	Vice President of Drug Discovery of Early Pre-Clinical Development

Important FAQs about investing in ESPR Stock from India :

What is Esperion Therapeutics share price today?

Esperion Therapeutics share price today is $2.06 as on August 16, 2025 at 1:29 AM IST at the close of the market. Esperion Therapeutics share today touched a day high of $2.18 and a low of $2.04.

What is the 52 week high and 52 week low for Esperion Therapeutics share?

Esperion Therapeutics share touched a 52 week high of $3.94 and a 52 week low of $0.69. Esperion Therapeutics stock price today, August 16, 2025 at 1:29 AM IST is trending at $2.06, lower by 47.72% versus the 52 week high.

How to invest in Esperion Therapeutics Stock (ESPR) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Esperion Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Esperion Therapeutics Shares that will get you 0.7282 shares as per Esperion Therapeutics share price of $2.06 per share as on August 16, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Esperion Therapeutics Stock (ESPR) from India?

Indian investors can start investing in Esperion Therapeutics (ESPR) shares with as little as ₹87.492 or $1 (as of August 16, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.92 in Esperion Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 16, 2025). Based on Esperion Therapeutics share’s latest price of $2.06 as on August 16, 2025 at 1:29 AM IST, you will get 4.8544 shares of Esperion Therapeutics. Learn more about fractional shares .

What are the returns that Esperion Therapeutics has given to Indian investors in the last 5 years?

Esperion Therapeutics stock has given -93.84% share price returns and 17.06% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?